The Experts below are selected from a list of 834 Experts worldwide ranked by ideXlab platform

Simon Rule - One of the best experts on this subject based on the ideXlab platform.

  • Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
    Clinical Medicine Insights. Oncology, 2012
    Co-Authors: Michelle Furtado, Simon Rule
    Abstract:

    Hodgkins’ Lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb therapy in the treatment on Non Hodgkins Lymphoma. The identification of CD30 as a potential target for treatment has led to the development of a new antibody-drug conjugate, brentuximab vedotin (SGN-35), which conjugates monomethyl auristatin E to an anti-CD30 antibody to deliver targeted toxicity to the malignant Reed Sternberg cells of HL. This review describes CD30 as an antibody target, and focuses on the antibody-drug conjugate brentuximab vedotin, including current knowledge of the mechanism of action, preclinical, clinical and pharmacokinetic data available for Brentuximab Vedotin.

  • Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin
    'SAGE Publications', 2012
    Co-Authors: Michelle Furtado, Simon Rule
    Abstract:

    Hodgkins Lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb therapy in the treatment on Non Hodgkins Lymphoma. The identification of CD30 as a potential target for treatment has led to the development of a new antibody-drug conjugate, brentuximab vedotin (SGN-35), which conjugates monomethyl auristatin E to an anti-CD30 antibody to deliver targeted toxicity to the malignant Reed Sternberg cells of HL. This review describes CD30 as an antibody target, and focuses on the antibody-drug conjugate brentuximab vedotin, including current knowledge of the mechanism of action, preclinical, clinical and pharmacokinetic data available for Brentuximab Vedotin

Michelle Furtado - One of the best experts on this subject based on the ideXlab platform.

  • Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
    Clinical Medicine Insights. Oncology, 2012
    Co-Authors: Michelle Furtado, Simon Rule
    Abstract:

    Hodgkins’ Lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb therapy in the treatment on Non Hodgkins Lymphoma. The identification of CD30 as a potential target for treatment has led to the development of a new antibody-drug conjugate, brentuximab vedotin (SGN-35), which conjugates monomethyl auristatin E to an anti-CD30 antibody to deliver targeted toxicity to the malignant Reed Sternberg cells of HL. This review describes CD30 as an antibody target, and focuses on the antibody-drug conjugate brentuximab vedotin, including current knowledge of the mechanism of action, preclinical, clinical and pharmacokinetic data available for Brentuximab Vedotin.

  • Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin
    'SAGE Publications', 2012
    Co-Authors: Michelle Furtado, Simon Rule
    Abstract:

    Hodgkins Lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb therapy in the treatment on Non Hodgkins Lymphoma. The identification of CD30 as a potential target for treatment has led to the development of a new antibody-drug conjugate, brentuximab vedotin (SGN-35), which conjugates monomethyl auristatin E to an anti-CD30 antibody to deliver targeted toxicity to the malignant Reed Sternberg cells of HL. This review describes CD30 as an antibody target, and focuses on the antibody-drug conjugate brentuximab vedotin, including current knowledge of the mechanism of action, preclinical, clinical and pharmacokinetic data available for Brentuximab Vedotin

Nazeel Ahmad - One of the best experts on this subject based on the ideXlab platform.

  • PET Scan Detects Prostate Cancer in a Patient with Hodgkins Lymphoma
    2015
    Co-Authors: Address Correspondence To Nazeel Ahmad, Connie A Keehn, John D Seigne, Merle Wade, Margaret Szabunio, Nazeel Ahmad
    Abstract:

    Abstract. Positron emission tomography (PET) is routinely used in the management of cancers such as lung, colorectal, esophageal, breast, Lymphoma, and melanoma. In urologic oncology, the role of PET has been less well defined and is currently under investigation. We report the first case of PET scan detection of prostate cancer in a patient with Hodgkins Lymphoma. (received 25 April 2003, accepted 15 May 2003

  • pet scan detects prostate cancer in a patient with Hodgkins Lymphoma
    Annals of Clinical and Laboratory Science, 2003
    Co-Authors: Connie A Keehn, John D Seigne, Merle Wade, Margaret Szabunio, Nazeel Ahmad
    Abstract:

    Positron emission tomography (PET) is routinely used in the management of cancers such as lung, colorectal, esophageal, breast, Lymphoma, and melanoma. In urologic oncology, the role of PET has been less well defined and is currently under investigation. We report the first case of PET scan detection of prostate cancer in a patient with Hodgkins Lymphoma.

Anupam Mondal - One of the best experts on this subject based on the ideXlab platform.

  • sagittal sinus tumor thrombosis in a case of nhl demonstrated on f 18 fdg pet ct
    Clinical Nuclear Medicine, 2011
    Co-Authors: Madhavi Tripathi, Maria M Dsouza, Jyotika Jain, Rima Kumari, Shefali Guliani, Santosh Pandey, Rajnish Sharma, Anupam Mondal
    Abstract:

    We report a case of a 60-year-old woman, diagnosed as a case of non Hodgkins Lymphoma (NHL), referred for F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) following 6 cycles of chemotherapy to evaluate response to therapy. The scan revealed a curvilinear pattern of FDG accumulation in the midline extending anteroposteriorly, just adjacent to the inner table of the skull on the fused PET/CT images with no corresponding abnormality on the low-dose CT. Because this site anatomically corresponded to that of the sagittal sinus, an MRI and magnetic resonance venography was advised which confirmed the presence of sagittal sinus tumor deposits. This case highlights the pattern of sagittal sinus tumor thrombosis on FDG PET/CT and the possibility of its occurrence in NHL.

Vikram P S J - One of the best experts on this subject based on the ideXlab platform.

  • Midline Lethal Granuloma Extra Nodal Natural Killer Cell / T Cell Lymphoma, Nasal Type- A Rare Presentation In Young Adult South Indian Female
    2014
    Co-Authors: Ramakrishnan R, Purushothaman P K, Vikram P S J
    Abstract:

    Abstract- Extranodal natural killer/T cell Lymphoma, nasal type, is a Non-Hodgkins Lymphoma, most commonly affecting the nasal cavity, paranasal sinuses and nasopharynx. Clinically it is characterised by destruction of facial tissues, commencing in the midline. In most cases it either arises from malignant transformation of natural killer cells (NK) or cytotoxic T cells. Extranodal NK/T cell Lymphoma, nasal type, is rare, but even rarer in females. The purpose of this article is to report a severe case of extranodal NK/T cell Lymphoma, nasal type, in young south Indian female and improvement of midfacial swelling after radiotherapy. Index Terms- Midline lethal granuloma, Extranodal NK/T cell lymphom